MIGRAINE MANAGEMENT

Joanna G. Katzman, M.D., M.S.P.H.
Associate Professor, Department of Neurosurgery
UNM Pain Center and Project ECHO Pain
University of New Mexico
Disclosure

- The presenter has no financial relationship to this program.
Objectives

1. The trigeminovascular theory of migraine etiology

2. Presenting signs and symptoms of migraine

3. The most common medications for prevention, abortive and rescue treatment
Outline

• Migraine throughout the decades
• Trigeminovascular theory
• Abortive treatment of migraine
• Prophylactic treatment of migraine
• Menstrual migraine
• Complicated migraine
• Medication overuse
• Rescue therapy
Early Classification of Migraine

- Common Migraine (without visual aura)
  - nausea, vomiting, photophobia

- Classical Migraine (with visual aura)
  - ex. scintillating scotoma thought to represent neuronal spreading depression

- Basilar Artery Migraine - ER Bikerstaff

- Migraines in Children - Bo Bille
1990s---Decade of the Triptans

• 7 “triptan” medications marketed in U.S. for abortive treatment

• Valproate FDA approved for migraine prophylaxis in U.S.

• Gababentin and Topiramate Open-label and double blinded trials for migraine prevention—positive

• Phase-Specific Treatment of Migraines
PHASE-SPECIFIC TREATMENT OF MIGRAINE

Phase I Prodrome

Phase II Aura

Phase III Early Headache

Phase IV Late Headache

Phase V Postdrome

OTCs, NSAIDs, Non-narcotic analgesics

Triptans

Rescue or rescue combinations

OTCs, NSAIDs

Phase-Specific Treatment of Migraine (Adapted from Cady)
Pain Syndrome

- Trigeminal nucleus activated
- Calcitonin gene – related peptide (CGRP) released by trigeminal nerve
- CGRP release causes vasodilation
- Plasma protein extravasation causes sterile inflammation in the dura matter
The Trigeminovascular Theory

Adapted from Lancet 1998;351:1045
ABORTIVE TREATMENT OF MIGRAINE

Selective 5-HT 1B/1D, receptor agonists (“Triptans”)

- Sumatriptan (Imitrex)
- Rizatriptan (Maxalt)
- Zolmitriptan (Zomig)
- Naratriptan (Amerge)
- Almotriptan (Axert)
- Frovatriptan (Frova)
- Eletriptan (Relpax)
<table>
<thead>
<tr>
<th></th>
<th>Eletriptan (Relpax)</th>
<th>Sumatriptan (Imitrex)</th>
<th>Rizatriptan (Maxalt)</th>
<th>Frovatriptan (Frova)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioavailability</strong></td>
<td>50%</td>
<td>15%</td>
<td>45%</td>
<td>20-30%</td>
</tr>
<tr>
<td><strong>Tmax</strong></td>
<td>1.5 hrs</td>
<td>2.5 hrs</td>
<td>1.5 hrs</td>
<td>2-4 hrs</td>
</tr>
<tr>
<td><strong>Half-Life</strong></td>
<td>4 hrs</td>
<td>2.5 hrs</td>
<td>2-3 hrs</td>
<td>26 hrs</td>
</tr>
<tr>
<td><strong>Efficacy at 2 hrs</strong></td>
<td>45-64%</td>
<td>46-62%</td>
<td>60-70%</td>
<td>37-46%</td>
</tr>
<tr>
<td><strong>Usual Dosage</strong></td>
<td>20-40 mg</td>
<td>25-50 mg</td>
<td>5-10 mg</td>
<td>2.5 mg</td>
</tr>
</tbody>
</table>
Triptan Medication Warning

- History of Cardiovascular Disease
- Uncontrolled Hypertension
- Complicated Migraine
- Age greater than 65
- Pregnancy
- Frequent use of other serotonergic medications
ADDITIONAL ABORTIVE TREATMENTS OF MIGRAINE

Non-selective serotonin agonists
  – Dihydroergomtamine
  – Ergotamine

Barbiturate-containing compounds
  – Fiorinal/Fioricet

Non-Steroidal anti-inflammatory drugs
  – Naproxen Sodium
<table>
<thead>
<tr>
<th>Drugs Approved by FDA for Migraine Prophylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methysergide maleate</td>
</tr>
<tr>
<td>Propanolol</td>
</tr>
<tr>
<td>Timolol</td>
</tr>
<tr>
<td>Divalproex sodium</td>
</tr>
<tr>
<td><em>Delayed-release tablets</em></td>
</tr>
<tr>
<td>Divalproex sodium</td>
</tr>
<tr>
<td><em>Extended-release tablets</em></td>
</tr>
<tr>
<td>Topiramate</td>
</tr>
</tbody>
</table>
OTHER PROPHYLACTIC MEDICATIONS

• Tricyclic Antidepressants
  Controlled trials showing benefits of amitriptyline in migraine, tension, posttraumatic and mixed headaches

• Calcium Antagonists
  Modest benefits of verapamil and flunarizine in double-blind placebo controlled studies
MIGRAINE PREVENTION AND NEUROPATHIC AGENTS

Mechanisms of Action

Anti-epileptic medications may prevent the release of vasoactive neuropeptides from the trigeminal sensory nerve

- CGRP (Calcitonin gene-related peptide)
- Neurokinin A
- Substance P
MENSTRUAL MIGRAINE

Introduction

• Link between estrogen and progesterone and migraines in women

• No gender difference with migraine in prepubertal children

• Migraine significantly more common in adult women than in men

• Peak incidence of migraine during adolescence (for women) and in second decade (for men)
MENSTRUALLY ASSOCIATED MIGRAINE

- 10% of women with any kind of migraine have onset of migraine headaches at menarche
- 33% of women with menstrual migraine have onset at menarche
- 3 Types of menstrually associated migraine:
  1. Menstrual Migraine (MM)
  2. True Menstrual Migraine (TMM)
  3. Pre-Menstrual Migraine (PMM)
EXOGENOUS ESTRADIOL DELAYS ONSET OF MIGRAINE

Plasma estradiol levels during normal cycle and estradiol-treated cycle. In this patient, treatment with estradiol postponed migraine for 6 days. (Reprinted from Somerville BW. The influence of progesterone and estradiol upon migraine. Headache 1972;12:93-102.)
ADVANCES IN MENSTRUAL MIGRAINE MANAGEMENT

Abortive Treatments

• Zolmitriptan – first large prospective double blind trial comparing zolmitriptan to placebo in a population of women with menstrual migraine
• Most triptans now used for hormonally mediated migraines

Preventive Treatments

• Estrogen replacement (Transdermal Estradiol)
• NSAIDS (Mefenamic acid)
COMPLICATED MIGRAINE

• Involves significant neurological deficits
• Recovery may take hours to days
• Rarely may represent a stroke
• Treatment should NOT include ergotamines or “Triptans”
• Treatments include Valproate, Verapamil and aspirin
• Oral contraceptive use contraindicated
MEDICATION OVERUSE

Analgesic-rebound headache
• Opiates
• Caffeine-containing combination analgesics

Triptan medication overuse

Treatment includes taper off offending agent(s) and placement on daily prophylaxis
THE ROLE OF RESCUE MEDICATIONS

• What are Rescue Medications?

• When are they used?

• Who needs to be “rescued”? 
CRITERIA FOR PRESCRIBING OPIOID MEDICATIONS FOR MIGRAINE SUFFERS

1. The patient reports identical previous migraine headaches, and

2. During the migraine, the sufferer is in moderate to severe distress, and

3. The patient has no history of substance abuse, and

4. At least one of the following should apply:
   – In the past, the patient consistently has not obtained relief from the 5-HT \textsubscript{1B/1D} agents (ie triptans and ergots)
   – In the past, the patient has consistently not obtained relief from the non-opioid agents.
   – The patient has used the maximum amounts of his/her usual abortive agents (eg triptans, NSAIDs) and the headache persists or recurs (see Table 1).
   – The usual migraine abortive agents (NSAIDs or 5-HT \textsubscript{1B/1D}) are contraindicated (see Table 1).
Project ECHO®
... promotes care in underserved areas

The mission of Project ECHO (Extension for Community Healthcare Outcomes) has been to develop the capacity to safely and effectively treat chronic, common, and complex diseases in rural and underserved areas, and to monitor outcomes of this treatment.

Project ECHO is funded in part by a grant from the Robert Wood Johnson Foundation and has received support from the New Mexico Legislature, the University of New Mexico, the New Mexico Department of Public Health and Agency for Healthcare Research and Quality.